For research use only. Not for therapeutic Use.
O-304 is a first-in-class, orally available pan-AMPK activator, which increases AMPK activity by suppressing the dephosphorylation of pAMPK. O-304 exhibits a great potential as a agent to treat type 2 diabetes (T2D) and associated cardiovascular complications [1][2].
O-304 increases glucose uptake in skeletal muscle, reduces β cell stress, and promotes β cell rest in diet-induced obese mice. O-304 reduces fasting plasma glucose levels and homeostasis model assessment of insulin resistance (HOMA-IR) in a proof-of-concept phase IIa clinical trial in type 2 diabetes (T2D) patients on Metformin[2].
| Catalog Number | I020231 |
| CAS Number | 1261289-04-6 |
| Synonyms | 4-chloro-N-[2-[(4-chlorophenyl)methyl]-3-oxo-1,2,4-thiadiazol-5-yl]benzamide |
| Molecular Formula | C16H11Cl2N3O2S |
| Purity | ≥95% |
| InChI | InChI=1S/C16H11Cl2N3O2S/c17-12-5-1-10(2-6-12)9-21-16(23)20-15(24-21)19-14(22)11-3-7-13(18)8-4-11/h1-8H,9H2,(H,19,20,22,23) |
| InChIKey | WEDWLYRQKUTOAX-UHFFFAOYSA-N |
| SMILES | C1=CC(=CC=C1CN2C(=O)N=C(S2)NC(=O)C3=CC=C(C=C3)Cl)Cl |
| Reference | [1]. Periodic Reporting for period 1-AMPK-DIAB (A small molecule AMP activated protein kinase (AMPK) activator, denoted O304, as a novelinnovative drug for the treatment of type 2 diabetes). |
